The deal reflects an enterprise value of about $615 million, according to a Nov. 29 news release from Boston Scientific.
Apollo Endosurgery’s product portfolio includes devices used during endoluminal surgery.
Mike Jones, senior vice president and president of endoscopy at Boston Scientific, said in the release that endoluminal surgery is a “core focus” for the company’s endoscopy business.
Boston Scientific expects to complete the acquisition during the first half of 2023.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
